smiths www.smiths.com

# SMITHS GROUP PLC ANNUAL GENERAL MEETING

**16 NOVEMBER 2020** 

#### **DISCLAIMER**

This presentation contains certain statements that are forward-looking statements. They appear in a number of places throughout this presentation and include statements regarding the intentions, beliefs and/or current expectations of Smiths Group plc (the "Company") and its subsidiaries (together, the "Group") and those of their respective officers, directors and employees concerning, amongst other things, the results of operations, financial condition, liquidity, prospects, growth, strategies and the businesses operated by the Group. By their nature, these statements involve uncertainty since future events and circumstances can cause results and developments to differ materially from those anticipated. The forward-looking statements reflect knowledge and information available at the date of preparation of this presentation and, unless otherwise required by applicable law, the Company undertakes no obligation to update or revise these forward-looking statements. Nothing in this presentation should be construed as a profit forecast. The Company and its directors accept no liability to third parties. This presentation contains brands that are trademarks and are registered and/or otherwise protected in accordance with applicable law.



# **Chairman of the meeting**

MARK SELIGMAN



### **Chairman's address**

SIR GEORGE BUCKLEY
CHAIRMAN



#### **Chief Executive's review**



### **Q1 Trading Update**






### FY2020 review - Leading now and in the future



Leading now – managing well through the uncertainty, executing the strategic restructuring programme and further portfolio upgrading

Leading in the future – strengthened position for consistent market outperformance

# **Putting our people and customers first**



### **Executing the strategic restructuring programme**



#### **Smiths Medical**



#### **Continued portfolio strengthening**

**Organic growth complemented** by disciplined M&A

1 DISPOSALS c.£535m proceeds

**10** ACQUISITIONS for c.£965m



TRANSACTIONS total value c.£1.5bn (FY16-FY20)



Smiths Detection - PathSensors

- August 2020
- Complements and accelerates biological capability to detect pathogens
- Broad end-market applications



#### Smiths Medical -**Access Scientific**

- May 2020
- Extends portfolio of vascular access solutions
- Enhance infection protection capabilities




#### Smiths Interconnect – Reflex **Photonics**

- October 2019
- Enhances our technological leadership in shock-resistant fibre optics
- Broad end-market applications



### **Designed to outperform**





#### Poll vote resolutions


- 1. Adoption of Annual Report FY2020
- 2. Approval of Directors' Remuneration Report
- Declaration of a final dividend
- 4. Election of Pam Cheng as a director
- 5. Election of Karin Hoeing as a director
- 6. Re-election of Sir George Buckley as a director
- 7. Re-election of Dame Ann Dowling as a director
- 8. Re-election of Tanya Fratto as a director
- 9. Re-election of William Seeger as a director
- 10. Re-election of Mark Seligman as a director
- 11. Re-election of John Shipsey as a director

- 12. Re-election of Andrew Reynolds Smith as a director
- 13. Re-election of Noel Tata as a director
- 14. Appointment of KPMG LLP as auditors
- 15. Auditors' remuneration
- 16. Authority to issue shares
- 17. Authority to disapply pre-emption rights
- 18. Additional authority to disapply pre-emption rights
- 19. Authority to make market purchases of shares
- 20. Authority to call general meetings on short notice
- 21. Authority to make political donations and expenditure



smiths www.smiths.com **QUESTIONS** & ANSWERS

### **Proxy votes cast**



smiths www.smiths.com

MAKING A SAFER, MORE EFFICIENT AND BETTER CONNECTED WORLD